Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral…
News
Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicine RESEARCH TRIANGLE PARK, N.C.,…
Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicine RESEARCH TRIANGLE PARK, N.C.,…
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to…
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to…
Salarius Pharmaceuticals CEO Issues Letter to Stockholders
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
Salarius Pharmaceuticals CEO Issues Letter to Stockholders
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation…
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation…
BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts
Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje…
BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts
Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje…
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept….
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept….
Better Choice Company Announces Management and Board Changes
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR)…
Better Choice Company Announces Management and Board Changes
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR)…
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s…